DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Stock Has Average Target Price of $12.00

Key Points

• Analyst consensus is “Moderate Buy”: Four of five analysts rate DiaMedica Therapeutics a buy, while one recommends selling; the average 12-month price target is $12.00 versus a recent share price of $7.66.
• Institutional investors own 10.12% of the company, with several firms recently increasing their positions or initiating new stakes.
• DiaMedica reported quarterly EPS of $(0.19), narrowly beating estimates of $(0.20). The clinical-stage biopharmaceutical company is developing DM199 for kidney and nervous-system disorders, including stroke and acute kidney injury.

DiaMedica Therapeutics, Inc. (NASDAQ:DMAC - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the five ratings firms that are currently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation and four have given a buy recommendation to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $12.00.

A number of equities analysts have recently issued reports on the stock. Weiss Ratings reiterated a "sell (d-)" rating on shares of DiaMedica Therapeutics in a research note on Friday, July 17th. HC Wainwright reissued a "buy" rating and issued a $12.00 price objective on shares of DiaMedica Therapeutics in a research note on Tuesday, August 11th.

Institutional Trading of DiaMedica Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. World Investment Advisors grew its stake in DiaMedica Therapeutics by 7.7% in the fourth quarter. World Investment Advisors now owns 36,975 shares of the company's stock valued at $294,000 after purchasing an additional 2,650 shares during the last quarter. Bank of America Corp DE lifted its position in shares of DiaMedica Therapeutics by 62.5% during the first quarter. Bank of America Corp DE now owns 42,768 shares of the company's stock valued at $290,000 after buying an additional 16,446 shares during the last quarter. AWM Investment Company Inc. purchased a new stake in shares of DiaMedica Therapeutics during the second quarter valued at about $253,000. Renaissance Technologies LLC bought a new stake in shares of DiaMedica Therapeutics in the 1st quarter valued at about $356,000. Finally, Sei Investments Co. boosted its holdings in shares of DiaMedica Therapeutics by 100.0% in the 1st quarter. Sei Investments Co. now owns 111,320 shares of the company's stock valued at $754,000 after buying an additional 55,660 shares in the last quarter. Institutional investors own 10.12% of the company's stock.

DiaMedica Therapeutics Stock Down 2.0%

Shares of NASDAQ DMAC opened at $7.66 on Thursday. The business has a fifty day simple moving average of $7.14 and a two-hundred day simple moving average of $6.69. The firm has a market cap of $413.07 million, a PE ratio of -10.64 and a beta of 0.92. DiaMedica Therapeutics has a twelve month low of $5.24 and a twelve month high of $10.42.

DiaMedica Therapeutics (NASDAQ:DMAC - Get Free Report) last posted its quarterly earnings results on Monday, August 10th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.20) by $0.01. On average, research analysts expect that DiaMedica Therapeutics will post -0.84 earnings per share for the current year.

About DiaMedica Therapeutics

DiaMedica Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for serious diseases affecting the kidneys and nervous system. The company's research is centered on biological pathways that may support tissue protection and recovery in conditions with limited treatment options.

Its lead investigational product, DM199, is a recombinant form of human tissue kallikrein-1, an enzyme involved in the kallikrein-kinin system. DiaMedica has studied DM199 in acute ischemic stroke and kidney-related disorders, including severe acute kidney injury.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.